We are a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical need in the areas of fibrosis, lysosomal storage disorders and oncology.
We have built a pipeline backed by a discovery engine with an extensive library of proprietary molecules, a wholly-owned research and development facility and a team with significant expertise and deep experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation.
Leveraging these assets and expertise, we are advancing two clinical candidates in three indications, as well as a deep pipeline of earlier stage programs.
Two royalty bearing collaborations with AbbVie and Boehringer Ingelheim
Three innovative clinical programs: FASST, NATIVE, IMPROVES
Pre-clinical pipeline in oncology and fibrosis
State of the art R&D capabilities inherited from Abbott, Solvay, Fournier
February 13, 2019
Publication of revenues and cash position
as of December 31, 2018
February 27, 2019
2018 annual financial results
Last update: Jan 14, 2019 at 17:35 CET
Previous close: €6.1
Day High: €6.26
Day Low: €6.1
April 16, 2018
May 17, 2017
January 12, 2017
January 4, 2019
September 4, 2018
June 6, 2018
Inventiva was co-founded by Frédéric Cren, Chairman, CEO and Co-Founder and Pierre Broqua, Chief Scientific Officer in Dijon in 2012.
Both have strong expertise within the areas of research, development and strategy and held senior research and executive positions at both Fournier and Solvay prior to founding Inventiva.
50 rue de Dijon
21121 Daix, France
Tel: +33 (0)3 80 44 75 00
Investor relations – Monique Kosse
Tel: +1 212 915 3820